Cyprotex PLC Launch of KeratinoSensTM Service
September 09 2014 - 2:01AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
09 September 2014
9(th) September 2014
Cyprotex PLC
Launch of KeratinoSens(TM) Service
An OECD guideline compliant, in vitro assay for skin
sensitisation
Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research
Organisation (CRO), today announces the launch of a new in vitro
screening service for determining skin sensitisation using the
KeratinoSens(TM) test method. In February this year, EURL ECVAM
(European Union Reference Laboratory for Alternatives to Animal
Testing) published its recommendation on the KeratinoSens(TM) assay
for use within an integrated strategy for skin sensitisation
testing. The draft OECD (Organisation for Economic Co-operation and
Development) test guidelines were released in May 2014 and Cyprotex
has validated the assay based on these guidelines.
Establishing in vitro alternatives to animal testing is a key
goal of the regulatory authorities especially in the cosmetics and
personal care markets where there has been a ban on animal testing
in many countries for these products. The KeratinoSens(TM) test
method extends Cyprotex's range of services in this segment. The
Company now has a comprehensive panel of relevant in vitro methods
for testing of skin and ocular irritation, skin corrosion, skin
sensitisation, skin absorption and phototoxicity which are
available to our customers in the personal care/cosmetics, chemical
and household products, and pharmaceutical industries.
A skin sensitiser is a substance that leads to an allergic
response following skin contact. This can manifest itself as
allergic contact dermatitis which is a major occupational and
environmental disease. Skin sensitisation is an important field of
research for Cyprotex. As well as offering standard test methods
such as the direct peptide reactivity assay (DPRA) and
KeratinoSens(TM) , CeeTox (acquired by Cyprotex in January 2014)
developed the SenCeeTox(R) method which uses a multiparametric
approach to evaluate skin sensitisation within a 3D skin model.
Cyprotex continue to develop and improve this technology and it is
a popular approach for screening finished products such as creams
or lotions and insoluble chemicals.
Cyprotex's Chief Executive Officer, Dr Anthony Baxter, said,
'Our acquisition of the business and assets of CeeTox in 2014 has
enabled Cyprotex to attract interest from new markets such as the
cosmetics/personal care and chemical industries. We are committed
to keeping up-to-date with the regulatory authorities recommended
approaches, and to developing our own novel technologies to better
understand complex issues such as skin sensitisation. The launch of
KeratinoSens(TM) expands our portfolio of assays ensuring we
maintain our competitive position in this area.'
For more information on our KeratinoSens(TM) service, please
contact enquiries@cyprotex.com
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
FTI Consulting Tel: +44 (0) 20
3727 1000
Simon Conway cyprotex@fticonsulting.com
Mo Noonan www.fticonsulting.com
Notes to Editors
Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 900 partners within the pharmaceutical and
biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services, extending from early drug discovery through to IND
submission. The acquisition of the assets and business of CeeTox in
January 2014 has enabled Cyprotex to expand its range of services
to target the personal care, cosmetics and chemical industries. The
Company's core capabilities include high quality in vitro ADME
screening services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, predictive modelling
using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK
prediction, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFVIARITIIS
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2024 to May 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From May 2023 to May 2024